Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 13776
Country/Region: Mozambique
Year: 2015
Main Partner: Center for Collaboration in Health
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $18,699,218 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $2,898,977
Care: TB/HIV (HVTB) $861,859
Care: Pediatric Care and Support (PDCS) $453,500
Health Systems Strengthening (OHSS) $600,000
Testing: HIV Testing and Counseling (HVCT) $967,701
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $2,052,114
Treatment: Adult Treatment (HTXS) $9,640,487
Treatment: Pediatric Treatment (PDTX) $1,224,580
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 23,612
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 202,425
CARE_NEW Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 63,675
FN_THER Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period 2016 18,218
FN_THER Number of PLHIV who were nutritionally assessed and found to be clinically undernourished 2016 24,289
FPINT_SITE Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services 2016 136
FPINT_SITE Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment 2016 136
GEND_GBV Number of people receiving post-GBV care 2016 3,114
HRH_PRE By Graduates: Nurses 2016 49
HRH_PRE Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre 2016 79
HRH_PRE Sum of Graduates disaggregates 2016 139
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 90,562
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 308,855
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 646
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 7,833
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 1,613
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 7,833
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 646
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 3,129
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 967
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 4,704
PMTCT_ARV Sum of New and Current disaggregates 2016 1,613
PMTCT_ARV Sum of New and Current disaggregates 2016 7,833
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2016 11,261
PMTCT_STAT By: Known positives at entry 2016 188
PMTCT_STAT By: Known positives at entry 2016 2,274
PMTCT_STAT By: Number of new positives identified 2016 458
PMTCT_STAT By: Number of new positives identified 2016 5,559
PMTCT_STAT Number of new ANC and L&D clients 2016 24,928
PMTCT_STAT Number of new ANC and L&D clients 2016 76,450
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 26,266
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 80,273
PMTCT_STAT Sum of Positives Status disaggregates 2016 646
PMTCT_STAT Sum of Positives Status disaggregates 2016 7,833
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2016 6,590
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2016 5,932
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 23,612
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 202,425
TX_CURR Age/Sex: <1 Female 2016 208
TX_CURR Age/Sex: <1 Female 2016 1,189
TX_CURR Age/Sex: <1 Male 2016 208
TX_CURR Age/Sex: <1 Male 2016 1,189
TX_CURR Age/Sex: 1-4 Female 2016 475
TX_CURR Age/Sex: 1-4 Female 2016 2,704
TX_CURR Age/Sex: 1-4 Male 2016 475
TX_CURR Age/Sex: 1-4 Male 2016 2,704
TX_CURR Age/Sex: 5-14 Female 2016 336
TX_CURR Age/Sex: 5-14 Female 2016 1,910
TX_CURR Age/Sex: 5-14 Male 2016 336
TX_CURR Age/Sex: 5-14 Male 2016 1,910
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 16,528
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 141,697
TX_CURR Sum of age/sex disaggregates 2016 11,606
TX_CURR Sum of Age/Sex disaggregations 2016 2,038
TX_NEW Aggregated Grouping by Age: <1 Male 2016 376
TX_NEW Aggregated Grouping by Age/Sex: <1 Female 2016 376
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2016 31,059
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2016 16,720
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2016 51,454
TX_NEW Pregnancy status 2016 4,704
TX_NEW Sum of Aggregated Age/Sex disaggregates 2016 47,779
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2016 13,574
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2016 18,271
Cross Cutting Budget Categories and Known Amounts Total: $923,062
Human Resources for Health $759,838
Motor Vehicles: Purchased $163,224